leisure time -WSS

leisure time

author：entertainment 2025-10-02 23:30:07 - browse：5

Colorful illustration of scientists using computers and Artificial Intelligence technology to visualize proteins for drug development – biotech coverage from STAT — Mike Reddy for STAT

David Reese calls it a “hinge moment” — the turning point when biotech and big tech merge to attack human disease with artificial intelligence.

At Amgen, where he’s led drug research and development since 2018, Reese said this moment has finally arrived. The proof lies not only in organizational changes, such as his recent appointment as the company’s first chief technology officer, but also in Amgen’s broader push to embed AI into every aspect of the drug discovery process.

“We’re now seeing 10-fold improvements in these (AI) models every six months,” said Reese, a medical oncologist by training. He added that the quickening pace of advancement means investing in the technology is no longer optional: “It’s something we must do to have a practical, pragmatic impact on drug discovery.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

leisure time

WSS

WATCH: Why do bright lights make us see spots?

Does good food count as health care? Study aims to find out

How housing is health care on Long Island

Childhood cancer progress stalls for Black, Hispanic kids: Report

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Wegovy, Zepbound and weight loss drugs that preserve muscle

Wikipedia

leisure time

entertainment

Guidelines to prevent youth baseball injuries need more muscle

Gain of function research would be limited under House proposal

Anesthesiologist group: stop taking Ozempic before surgery

A daunting task: navigating dual Medicare, Medicaid eligibility

Hollywood unions extend contract negotiations for actors

Generate Biomedicines machine learning biotech raises $273M

Medicare details structure of new drug price negotiation program

Popular nasal decongestant doesn't actually relieve congestion

The high cost of giving birth even with insurance

World's first CRISPR

hotspot

Acelyrin, a rare IPO success, stumbles in its first big test

How to make the FDA’s new prescription one

Telehealth for opioid use disorder is lifesaving

In key trial, Verve's treatment lowers cholesterol levels in patients

Popular nasal decongestant doesn't actually relieve congestion

Hospitals look to new technology to keep health care workers safe

hotspot

knowledge

leisure time

knowledge